Moderna Inc (MRNA)vsNeuphoria Therapeutics Inc (NEUP)
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
NEUP
Neuphoria Therapeutics Inc
$3.36
-0.88%
HEALTHCARE · Cap: $18.61M
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 189646% more annual revenue ($2.23B vs $1.17M). NEUP leads profitability with a 0.0% profit margin vs -141.4%. NEUP earns a higher WallStSmart Score of 28/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NEUP
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Intrinsic value data unavailable for NEUP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NEUP
The strongest argument for NEUP centers on Price/Book, Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NEUP
The primary concerns for NEUP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NEUP is a value play — different risk/reward profiles.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NEUP generates stronger free cash flow (1M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NEUP scores higher overall (28/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Neuphoria Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is a groundbreaking biotechnology firm focused on revolutionizing mental health disorders treatment via psychedelic compounds and advanced drug delivery systems. The company boasts a promising pipeline of preclinical candidates, strategically targeting significant unmet needs within the mental healthcare sector, coinciding with the increasing acceptance of alternative therapies. As a frontrunner in the rapidly evolving psychedelic therapy market, Neuphoria offers a compelling investment proposition for institutional investors keen on supporting innovative solutions that may fundamentally alter the landscape of mental health treatment.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?